Duality S.A.

Equities

DUA

PLDLITY00010

End-of-day quote Warsaw S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
1.665 ^PLN	-3.20%		-8.52%	+12.50%

20/03	Duality S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/03	BioNTech to Present Clinical Data Updates on Cancer Vaccine Candidates	MT

Duality S.A. Reports Earnings Results for the Full Year Ended December 31, 2023

March 20, 2024 at 09:54 pm IST

Duality S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was PLN 4.08 million compared to PLN 479.37 million a year ago. Net loss was PLN 3.6 million compared to net income of PLN 0.519707 million a year ago.

Latest news about Duality S.A.

Duality S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
BioNTech to Present Clinical Data Updates on Cancer Vaccine Candidates	11/03	MT
Tod's CEO says he has no plans to sell 'family business'	23/02	RE
BioNTech, Duality Biologics Obtain FDA Fast Track Designation for Ovarian Cancer Therapy Candidate	31/01	MT
BioNTech's Cancer Therapy Candidate Obtains Fast-track Designation from US FDA	31/01	MT
BioNTech, Duality Biologics Initiate Phase 3 Trial of Breast Cancer Drug	22/01	MT
BioNTech Begins Late-stage Study for Metastatic Breast Cancer Therapy Candidate	22/01	MT
BioNTech challenges AstraZeneca with breast cancer precision drug trial	22/01	RE
BioNTech, Duality Biologics Get US FDA Breakthrough Therapy Designation for Uterine Cancer Drug Candidate	21/12	MT
Duality S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Australia's Albanese to highlight trade on China visit as ties warm	03/11	RE
Duality S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Introducing Janus, the exotic 'two-faced' white dwarf star	21/23/21	RE
HBM Holdings, Beigene Sign License Deal for Antibody-Drug Conjugate Program; HBM Shares Soar 20%	14/23/14	MT
Duality S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
BioNTech, DualityBio Sign Strategic Partnership to Develop ADC Therapeutics to Treat Solid Tumors	03/23/03	MT
BioNTech Partners With DualityBio to Develop Cancer Treatments	03/23/03	MT
BioNTech, Duality Biologics Enter Licensing Agreement for Cancer Treatments	03/23/03	DJ
Credit Suisse on Hydro One: "All About Ontario with the Duality of Delivering Decarbonization and Defensive Growth"	31/23/31	MT
Swiss neutrality on the line as arms-for-Ukraine debate heats up	07/23/07	RE
Swiss neutrality on the line as arms-for-Ukraine debate heats up	06/23/06	RE
Analysis-Swiss neutrality on the line as arms-for-Ukraine debate heats up	06/23/06	RE
Historic UK satellite launch may spur military appetite	09/23/09	RE
Duality S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Duality S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI

Chart Duality S.A.

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data